Search results for "chronic hepatiti"

showing 10 items of 168 documents

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis

2021

ObjectiveLiver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies.DesignIndividual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were c…

Liver CirrhosisMaleCirrhosisLIVER STIFFNESS MEASUREMENTBiopsy[SDV]Life Sciences [q-bio]biostatisticsGastroenterologyDISEASEbiostatistics; clinical decision making; fatty liver; hepatic fibrosis0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosishepatic fibrosis2. Zero hunger0303 health sciencesmedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISTRANSIENT ELASTOGRAPHYFatty liverGastroenterologyCHRONIC HEPATITISMiddle Aged3. Good healthSettore AGR/03 - Arboricoltura Generale E Coltivazioni ArboreeLiverLiver biopsyBIOPSYElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyMedian bodymedicine.medical_specialtyCONTROLLED ATTENUATION PARAMETER610 Medicine & healthclinical decision making03 medical and health sciencesInternal medicineSCOREmedicineHumansbiostatistics clinical decision making fatty liver hepatic fibrosisfatty liver030304 developmental biologyReceiver operating characteristicbusiness.industrymedicine.diseaseFibrosisDiabetes Mellitus Type 2XL PROBEbusinessHepatic fibrosisTransient elastographyBiomarkersPROSPECTIVE DERIVATIONGut : the journal of the British Society for Gastroenterology
researchProduct

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cir…

2013

Genetic factors can influence the outcome of antiviral therapy in chronic hepatitis C (HCV). We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-Interferon and ribavirin. A prospective cohort of 233 patients with compensated cirrhosis received 1-1.5 μg/kg/week of Peg-Interferon alpha-2b plus 1000-1200 mg/day of RBV for 48 weeks. A sustained virologic response (SVR) was achieved in 27% of patients. On multivariate logistic analysis, the absence of oesophageal varices (OR 3.64 CI 95% 1.27-10.44 P = 0.016), infection with genotype 2 or 3 (OR 4.06, CI 95% 1.08-15.26, P = 0.038), C/C all…

Liver CirrhosisMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaAnemia HemolyticGenotypeHepacivirusInterferon alpha-2Esophageal and Gastric VaricesAntiviral AgentsPolymorphism Single NucleotidePolyethylene GlycolsSettore BIO/13 - Biologia ApplicataRibavirinHumanschronic hepatitis C cirrhosis IL-28B inosine triphosphatase sustained virologic responseProspective StudiesPyrophosphatasesGenetic Association StudiesAgedSettore MED/12 - GastroenterologiaDose-Response Relationship DrugInterleukinsInterferon-alphaSequence Analysis DNAHepatitis C ChronicMiddle AgedRecombinant ProteinsLogistic ModelsTreatment OutcomeMultivariate AnalysisDrug Therapy CombinationFemaleInterferonsJournal of viral hepatitis
researchProduct

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease.

2008

Background & Aims: The natural course of chronic hepatitis C (CHC) in children is not well understood. The aim of this study was to assess the long-term course of CHC in a large sample of otherwise healthy children. Methods: From 1990 to 2005, 504 consecutive antihepatitis C virus (HCV)-positive children were enrolled at 12 centers of a national observatory and were followed up retrospectively/prospectively. Results: Putative exposure was perinatal in 283 (56.2%) cases, parenteral in 158 (31.3%), and unknown in 63 (12.5%). At baseline, 477 (94.6%) cases were HCV RNA seropositive, 118 (24.7%) of which were treated with standard interferon α. Ten years after putative exposure, the outcome in …

Liver CirrhosisMaleTime FactorsHepacivirusHepacivirusChronic hepatitis CGastroenterologyLiver diseaseViralProspective StudiesChronicProspective cohort studyChildChildrenchronic epatitis C; long term course; childrenbiologyHazard ratioGastroenterologyHepatitis CViral LoadHepatitis CTreatment OutcomeItalyChild PreschoolHCVDisease ProgressionRNA ViralFemaleViral loadmedicine.medical_specialtyAdolescentGenotypeAlpha interferonSocio-culturaleViremiaAntiviral AgentsRisk AssessmentHEPATITISInternal medicinemedicineHumansViremiaAdolescent; Antiviral Agents; Child; Child Preschool; Disease Progression; Female; Genotype; Hepatitis C Chronic; Humans; Infant; Interferon-alpha; Italy; Liver Cirrhosis; Male; Proportional Hazards Models; Prospective Studies; RNA Viral; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; Viral Load; Viremia; Hepacivirus; GastroenterologyPreschoolProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryLong-term courseInfantInterferon-alphaHepatitis C Chronicbiology.organism_classificationmedicine.diseaseImmunologyRNAbusinessGastroenterology
researchProduct

SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C

2009

The staging of liver fibrosis is pivotal for defining the prognosis and indications for therapy in hepatitis C. Although liver biopsy remains the gold standard, several noninvasive methods are under evaluation for clinical use. The aim of this study was to validate the recently described sequential algorithm for fibrosis evaluation (SAFE) biopsy, which detects significant fibrosis (≥F2 by METAVIR) and cirrhosis (F4) by combining the AST-to-platelet ratio index and Fibrotest-Fibrosure, thereby limiting liver biopsy to cases not adequately classifiable by noninvasive markers. Hepatitis C virus (HCV) patients (2035) were enrolled in nine locations in Europe and the United States. The diagnosti…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBiopsyGastroenterologyFibrosisInternal medicineBiopsymedicineHumansLiver biopsy chronic hepatitia CNeoplasm StagingRetrospective StudiesHepatitisSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryHepatitis CHepatitis C ChronicMiddle AgedHepatologymedicine.diseaseLiver biopsyFemaleHepatic fibrosisbusinessAlgorithmsHepatology
researchProduct

Reproductive status is associated with the severity of fibrosis in women with hepatitis C.

2012

Introduction Chronic hepatitis C is the main cause of death in patients with end-stage liver disease. Prognosis depends on the increase of fibrosis, whose progression is twice as rapid in men as in women. Aim of the study was to evaluate the effects of reproductive stage on fibrosis severity in women and to compare these findings with age-matched men. Materials and Methods A retrospective study of 710 consecutive patients with biopsy-proven chronic hepatitis C was conducted, using data from a clinical database of two tertiary Italian care centers. Four age-matched groups of men served as controls. Data about demographics, biochemistry, liver biopsy and ultrasonography were analyzed. Contrib…

Liver CirrhosisMalemedicine.medical_specialtyGastroenterology and hepatologyLiver CirrhosiPhysiologylcsh:MedicineViral diseasesChronic hepatitis CSeverity of Illness IndexHepatitisLiver diseaseEndocrinologyFibrosisRetrospective StudieSeverity of illnessmedicinegenderHumansReproductive EndocrinologyChronic hepatitis C; genderlcsh:ScienceTestosteroneLiver diseasesRetrospective StudiesGynecologyMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RCase-control studyHepatitis Cmedicine.diseaseHepatitis CMenopauseInfectious hepatitisCirrhosisLiver biopsyCase-Control StudiesMedicineInfectious diseasesWomen's HealthFemalelcsh:QbusinessCase-Control StudieInfertility FemaleResearch ArticleHumanPLoS ONE
researchProduct

Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C.

2008

Eosinophilic infiltrate of liver tissue is described in primary cholestatic diseases, hepatic allograft rejection and drug-induced liver injury, but its significance and its implications in chronic hepatitis C are unknown. The aim of this study was to investigate the clinical significance of eosinophilic liver infiltrate in patients with chronic hepatitis C. We retrospectively evaluated 147 patients with chronic hepatitis C. The presence of eosinophilic infiltrate was investigated in liver biopsies, and a numeric count of eosinophilic leucocytes in every portal tract was assessed. An eosinophilic infiltrate of liver tissue (> or =3 cells evaluated in the portal / periportal spaces) was obse…

Liver CirrhosisMalemedicine.medical_specialtyPathologyLiver steatosisSettore MED/08 - Anatomia PatologicaChronic hepatitis CGastroenterologyFibrosisVirologyInternal medicineEosinophiliaEosinophilicHumansMedicineClinical significanceRetrospective StudiesLiver injuryHepatologymedicine.diagnostic_testbusiness.industryLiver fibrosiOdds ratioHepatitis CHepatitis C ChronicLiver biopsymedicine.diseaseEosinophilsFatty LiverInfectious DiseasesLiverLiver biopsyFemaleEosinophilic infiltrateSteatosisDrugChronic hepatitis C; Drugs; Eosinophilic infiltrate; Liver biopsy; Liver fibrosis; Liver steatosisbusiness
researchProduct

Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease

2021

Traditional histological evaluation for grading liver disease severity is based on subjective and semi-quantitative scores. We examined the relationship between digital pathology analysis and corresponding scoring systems for the assessment of hepatic necroinflammatory activity. A prospective, multicenter study including 156 patients with chronic liver disease (74% nonalcoholic fatty liver disease-NAFLD, 26% chronic hepatitis-CH etiologies) was performed. Inflammation was graded according to the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network system and METAVIR score. Whole-slide digital image analysis based on quantitative (I-score: inflammation ratio) and morphometric (C-sco…

Liver CirrhosisMalenonalcoholic fatty liver diseaseMiddle AgedFibrosisMicrobiologyBiochemistryArticleQR1-502digital pathology; inflammation; nonalcoholic fatty liver disease; chronic hepatitisLiverNon-alcoholic Fatty Liver DiseaseinflammationHumanschronic hepatitisdigital pathologyMolecular BiologyBiomolecules
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct

Hepatitis B Virus-Associated Hepatocellular Carcinoma

2022

Hepatitis B virus (HBV) is DNA-based virus, member of the Hepadnaviridae family, which can cause liver disease and increased risk of hepatocellular carcinoma (HCC) in infected individuals, replicating within the hepatocytes and interacting with several cellular proteins. Chronic hepatitis B can progressively lead to liver cirrhosis, which is an independent risk factor for HCC. Complications as liver decompensation or HCC impact the survival of HBV patients and concurrent HDV infection worsens the disease. The available data provide evidence that HBV infection is associated with the risk of developing HCC with or without an underlying liver cirrhosis, due to various direct and indirect mecha…

Liver CirrhosisSettore MED/12 - GastroenterologiaHepatitis B virusCarcinoma Hepatocellularhepatocellular carcinoma.hepatitis B viruLiver NeoplasmsHepatitis Bhepatitis D viruInfectious DiseasesVirologyTumor MicroenvironmentHumanshepatitis B chronic hepatitiViruses
researchProduct

Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma

2012

Interleukin-6 (IL-6) is a pleiotropic cytokine which is expressed in many inflammatory cells in response to different types of stimuli, regulating a number of biological processes. The IL-6 gene is polymorphic in both the 5’ and 3’ flanking regions and more than 150 single nucleotide polymorphisms have been identified so far. Genetic polymorphisms of IL-6 may affect the outcomes of several diseases, where the presence of high levels of circulating IL-6 have been correlated to the stage and/or the progression of the disease itself. The -174 G/C polymorphism is a frequent polymorphism, that is located in the upstream regulatory region of the IL-6 gene and affects IL-6 production. However, the…

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusSingle-nucleotide polymorphismBiologyChronic liver diseasemedicine.disease_causePolymorphism Single NucleotideGastroenterologyHepatitis B ChronicNon-alcoholic Fatty Liver DiseaseRisk FactorsChronic hepatitis Hepatocellular carcinoma Interleukin-6 Liver cirrhosis Single nucleotide polymorphismsInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseTopic HighlightLiver Diseases AlcoholicInterleukin-6Liver NeoplasmsFatty liverGastroenterologyGeneral MedicineHepatitis C ChronicHepatitis Bmedicine.diseaseFatty LiverHepatitis AutoimmunePhenotypeHepatocellular carcinomaImmunologySteatohepatitisWorld Journal of Gastroenterology
researchProduct